Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 11—November 2019
Research Letter

Severe Fever with Thrombocytopenia Syndrome Virus RNA in Semen, Japan

Figures
Article Metrics
19
citations of this article
EID Journal Metrics on Scopus
Author affiliations: Nagasaki University, Nagasaki, Japan

Cite This Article

Abstract

Severe fever with thrombocytopenia syndrome virus (SFTSV) can be transmitted between humans. We describe a case of severe fever with thrombocytopenia syndrome in which SFTSV RNA was detected in semen after its disappearance from serum. Our findings indicate possible sexual transmission of this emerging virus.

Severe fever with thrombocytopenia syndrome (SFTS) is a life-threatening emerging infectious disease caused by severe fever with thrombocytopenia syndrome virus (SFTSV), a tickborne virus (genus Banyang virus, family Phenuiviridae). Recently, the person-to-person transmission of SFTSV has been described (1,2), and the most common risk factor of the transmission is direct blood exposure (2). However, SFTSV RNA has been detected in nonblood samples, such as throat, urine, and fecal specimens, especially in fatal cases (3). Asymptomatic infections through personal contact without blood exposure have also been reported (1). We describe a case in which viral RNA was detected in semen after viral RNA clearance from blood.

During May 2018, a previously healthy 50-year-old man hunted boar in the Goto Islands in western Japan. Eight days after hunting, he experienced high fever, myalgia, and diarrhea. He did not have hematuria or bloody diarrhea. Disturbance of consciousness occurred 6 days after symptom onset; on that day, he visited a local hospital and was referred to and admitted to Nagasaki University Hospital (Nagasaki, Japan). Body temperature was 39.0°C, and he was disoriented; Glasgow coma scale score was 9. He had no jaundice, signs of meningeal irritation, or apparent tick bites. Laboratory tests at admission had the following results: leukocytes 2.4 × 103 cells/μL; platelets 35 × 103/μL; serum creatine 3.04 mg/dL; aspartate aminotransferase 508 U/L; lactate dehydrogenase 1,404 U/L; and creatine kinase 15,449 U/L.

Because of the patient’s low platelet count and other suggestive signs and symptoms, we suspected SFTS. Serum SFTSV RNA level was 2.03 × 108 copies/mL by real-time reverse transcription PCR (RT-PCR) analysis (Appendix). We confirmed diagnosis of SFTS on the basis of these results; however, we did not detect viral RNA in a urine sample. We conducted RT-PCR tests of semen and urine using procedures developed for serum; all RT-PCR tests were performed in the Department of Virology, Institute of Tropical Medicine, Nagasaki University, Nagasaki.

We considered this case severe, with multiple poor prognosis factors, such as disturbance of consciousness, laboratory data, and high viral load in serum (4). We performed palliative therapy, including continuous hemodiafiltration, mechanical ventilation, and central venous nutrition. In addition, we treated the patient with recombinant human soluble thrombomodulin for disseminated intravascular coagulation (380 U/kg/d for 6 d) and granulocyte colony-stimulating factor (filgrastim) for neutropenia (300 μg on the third hospital day). We also administered intravenous immunoglobulin (5,000 mg/d for 3 d), because it has been reported effective for SFTS (5), and the patient received platelet transfusions for severe thrombocytopenia.

Figure

Thumbnail of Laboratory data and viral loads during course of illness for patient with severe fever with thrombocytopenia syndrome, Japan. A) Leukocyte and platelet counts; B) AST, LDH, and CK levels; C) viral loads in serum, semen, and saliva. Dashed line in panel C indicates detection threshold (2 x 102 copies/mL). AST, aspartate aminotransferase; CK, creatine kinase; LDH, lactate dehydrogenase.

Figure. Laboratory data and viral loads during course of illness for patient with severe fever with thrombocytopenia syndrome, Japan. A) Leukocyte and platelet counts; B) AST, LDH, and CK levels; C) viral...

We observed restoration of platelet count 10 days after symptom onset. Other abnormal laboratory findings recovered 7–13 days after symptom onset. The viral load in serum began to decrease from day 8 after onset and became negative on day 30 after onset. Although the patient’s general status was gradually improved and laboratory tests recovered to almost normal levels by day 30, we detected SFTSV RNA at 2.4 × 105 copies/mL in his semen that day. On day 44, we could no longer detect semen SFTSV RNA, and he was discharged on day 51 after onset (Figure).

In this study, SFTSV RNA was detected in semen, and SFTSV persisted longer in semen than in serum. It is well known that some viruses, such as Zika virus and Ebola virus, can be sexually transmitted; these viruses have been detected in semen for a prolonged period after symptom onset (6,7). Thus, we considered the potential risk for sexual transmission of SFTSV.

Compared with that of Zika and Ebola viruses, the clinical significance of potential sexual transmission of SFTSV is unknown. However, this possibility should be taken into consideration in sexually active patients with SFTSV. Our findings suggest the need for further studies of the genital fluid of SFTS patients, women as well as men, and counseling regarding sexual behavior for these patients.

Dr. Koga is a member of the Respiratory and Infectious Diseases Departments at Nagasaki University. His research interests include viral and fungal infections.

Top

References

  1. Huang  D, Jiang  Y, Liu  X, Wang  B, Shi  J, Su  Z, et al. A cluster of symptomatic and asymptomatic infections of severe fever with thrombocytopenia syndrome caused by person-to-person transmission. Am J Trop Med Hyg. 2017;97:396402. DOIPubMedGoogle Scholar
  2. Chen  H, Hu  K, Zou  J, Xiao  J. A cluster of cases of human-to-human transmission caused by severe fever with thrombocytopenia syndrome bunyavirus. Int J Infect Dis. 2013;17:e2068. DOIPubMedGoogle Scholar
  3. Zhang  YZ, He  YW, Dai  YA, Xiong  Y, Zheng  H, Zhou  DJ, et al. Hemorrhagic fever caused by a novel Bunyavirus in China: pathogenesis and correlates of fatal outcome. Clin Infect Dis. 2012;54:52733. DOIPubMedGoogle Scholar
  4. Gai  ZT, Zhang  Y, Liang  MF, Jin  C, Zhang  S, Zhu  CB, et al. Clinical progress and risk factors for death in severe fever with thrombocytopenia syndrome patients. J Infect Dis. 2012;206:1095102. DOIPubMedGoogle Scholar
  5. Kim  UJ, Kim  DM, Ahn  JH, Kang  SJ, Jang  HC, Park  KH, et al. Successful treatment of rapidly progressing severe fever with thrombocytopenia syndrome with neurological complications using intravenous immunoglobulin and corticosteroid. Antivir Ther. 2016;21:63740. DOIPubMedGoogle Scholar
  6. Fischer  WA, Brown  J, Wohl  DA, Loftis  AJ, Tozay  S, Reeves  E, et al. Ebola virus ribonucleic acid detection in semen more than two years after resolution of acute Ebola virus infection. Open Forum Infect Dis. 2017;4:ofx155. DOIPubMedGoogle Scholar
  7. Medina  FA, Torres  G, Acevedo  J, Fonseca  S, Casiano  L, De León-Rodríguez  CM, et al. Duration of the presence of infectious Zika virus in semen and serum. J Infect Dis. 2019;219:3140.PubMedGoogle Scholar

Top

Figure

Top

Cite This Article

DOI: 10.3201/eid2511.190061

Original Publication Date: September 30, 2019

Table of Contents – Volume 25, Number 11—November 2019

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Takahiro Takazono, Nagasaki University Department of Infectious Diseases, Graduate School of Biomedical Sciences, 7-1 Sakamoto, Nagasaki 852-8501, Japan

Send To

10000 character(s) remaining.

Top

Page created: October 15, 2019
Page updated: October 15, 2019
Page reviewed: October 15, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external